SecBot SecBot
SECBOTREPLAY Home › Report › MDGL

MDGL · Madrigal Pharmaceuticals reported Q2 2026 Rezdiffra net sales of…

MADRIGAL PHARMACEUTICALS, INC. · 8-K filed Jul 30, 2026 at 07:03 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 30, 2026 at 07:03 ET

Madrigal Pharmaceuticals reported Q2 2026 Rezdiffra net sales of $364.3M, up 71% YoY, beating consensus revenue estimates. The net loss per share of -$1.99 also beat consensus estimates of -$2.23. The company continues to see strong commercial execution with over 49,000 patients on therapy and advanced its pipeline with MGL-2086 entering Phase 1, reinforcing its leadership in the MASH market.

  • Q2 2026 Rezdiffra net sales of $364.3M, up 71% YoY from $212.8M
  • Net loss of $57.9M or -$1.99 per share, beating consensus of -$2.23
  • Over 49,000 patients on Rezdiffra as of June 30, 2026, more than doubling from Q2 2025
  • Cash position of $838.9M as of June 30, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access